Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Cancer Supportive Care Drugs Market

Cancer Supportive Care Drugs Market Trends

Report ID: GMI6489
Published Date: Aug 2023
Report Format: PDF

Download Free Sample

Cancer Supportive Care Drugs Market Trends

Some key trends in the industry include a growing focus on personalized medicine in supportive care, the development of targeted therapies for specific side effects of cancer treatment, the integration of digital health technologies, including mobile apps and telemedicine platforms, into supportive care programs. Additionally, there is a growing emphasis on managing long-term treatment-related effects, an increasing use of combination therapies that include supportive care drugs alongside cancer treatments, and the development of biologic agents, such as monoclonal antibodies, to target specific pathways involved in treatment-related symptoms. These trends reflect efforts to enhance the overall quality of life for cancer patients by efficiently managing treatment-related symptoms and providing the most effective and comprehensive supportive care.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for cancer supportive care drugs was worth USD 14.4 billion in 2022 and is estimated to expand at 1.9% CAGR from 2023-2032 attributed to the growing progress in cancer treatments, such aschemotherapy, radiation therapy, targeted therapy, and immunotherapy.

The G-CSFs (granulocyte-colony stimulating factors) segment accounted for 22.8% share in the cancer-supportive care drugs market owing to its extensive usage to avoid neutropenia.

Asia Pacific industry is set to witness 2.3% CAGR from 2023-2032 and reach USD 6.1 billion by 2032 driven by the rising incidence of cancer due to population growth, aging, changing lifestyles, and environmental factors.

Some of the top companies in the industry are Amgen, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Heron Therapeutics, Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Teva Pharmaceuticals Industries Ltd., and Fagron Group.